Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Net Margin (2023 - 2025)

Entrada Therapeutics has reported Net Margin over the past 3 years, most recently at 3013.09% for Q4 2025.

  • Quarterly results put Net Margin at 3013.09% for Q4 2025, down 301596.0% from a year ago — trailing twelve months through Dec 2025 was 565.65% (down 59678.0% YoY), and the annual figure for FY2025 was 565.38%, down 59651.0%.
  • Net Margin for Q4 2025 was 3013.09% at Entrada Therapeutics, down from 2737.3% in the prior quarter.
  • Over the last five years, Net Margin for TRDA hit a ceiling of 81.08% in Q3 2023 and a floor of 3013.09% in Q4 2025.
  • Median Net Margin over the past 3 years was 48.96% (2023), compared with a mean of 677.31%.
  • Biggest five-year swings in Net Margin: skyrocketed 20055bps in 2024 and later crashed -301596bps in 2025.
  • Entrada Therapeutics' Net Margin stood at 22.81% in 2023, then skyrocketed by 113bps to 2.88% in 2024, then plummeted by -104824bps to 3013.09% in 2025.
  • The last three reported values for Net Margin were 3013.09% (Q4 2025), 2737.3% (Q3 2025), and 2211.54% (Q2 2025) per Business Quant data.